用于治疗多发性硬化症的 S1P 靶点小分子药物及其专利研究

姜华; 焦洪涛; 钱丽娜; 黄璐

doi:10.20251/j.cnki.1003-3734.2026.16.001

中国新药杂志 ›› 2026, Vol. 35 ›› Issue (16) : 1681 -1688. DOI: 10.20251/j.cnki.1003-3734.2026.16.001

新药述评与论坛

用于治疗多发性硬化症的 S1P 靶点小分子药物及其专利研究

^1,2

^2*

^1,4,5,6*

作者信息 +

Sphingosine-1-phosphate-targeted small molecule drugs for the treatment of multiple sclerosis and the patent research

^1,2

^2*

^1,4,5,6*

Author information +

文章历史 +

PDF (1085K)

摘要

本文梳理了全球已获批上市与正在研发中的用于治疗多发性硬化症的鞘氨醇-1-磷酸 (sphin-gosine-1-phosphate,S1P) 靶点小分子药物品种情况,对其中4个已上市药物芬戈莫德、西尼莫德、奥扎莫德和珀奈莫德的研发进展以及涉及其化合物、药物制剂、新用途等不同技术主题已公开的专利进行研究和分析,以期为医药企业在进行立项与开发有关药物以及进行新的专利挖掘、专利申请与布局时,提供有效的产品信息和专利信息。

Abstract

In this paper, four sphingosine-1-phosphate (S1P) targeted small molecule drugs for the treatment of multiple sclerosis which have been marketed worldwide, and their patent information were unscrambled and researched.The development progress of fingolimod, siponimod, ozanimod and ponesimod, as well as their published patents about product, formulation, new use, et al, were studied and analyzed to provide effective patent information and references for pharmaceutical enterprises in China in the process of establishing and developing related drugs, as well as new patent mining, patent application and layout.

关键词

多发性硬化症 / 鞘氨醇-1-磷酸 / 芬戈莫德 / 西尼莫德 / 奥扎莫德 / 珀奈莫德 / 专利研究

Key words

multiple sclerosis / sphingosine-1-phosphate / fingolimod / siponimod / ozanimod / ponesimod / patent research

引用本文

引用格式 ▾

姜华, 焦洪涛, 钱丽娜, 黄璐. 用于治疗多发性硬化症的 S1P 靶点小分子药物及其专利研究[J]. 中国新药杂志, 2026, 35(16): 1681-1688 DOI:10.20251/j.cnki.1003-3734.2026.16.001

登录浏览全文

4963

注册一个新账户忘记密码

参考文献

[1] 徐珍媚. 鞘氨醇-1-磷酸受体1激活及其偏向性机理的结构基础研究[D].哈尔滨:哈尔滨工业大学,2022.
[2] TSAI HC,HAN MH.Sphingosine-1-phosphate (S1P) and S1P signaling pathway:therapeutic targets in autoimmunity and in-flammation[J].Drugs,2016,76 (11):1067-1079.
[3] 吕梦娜,李建斌,吴锐.S1P/S1PRs 信号通路在多发性硬化症中的研究进展[J].医学综述,2024,30 (15):1806-1812.
[4] FAN XH,LIU LL,SHI Y,et al.Recent advances of the func-tion of sphingosine 1-phosphate (S1P) receptor S1P3[J].J Cell Physiol,2021,236 (3):1564-1578.
[5] KARUSSIS D.The diagnosis of multiple sclerosis and the various related demyelinating syndromes:a critical review[J].J Autoim-mun,2014,48-49:134-142.
[6] Clarivate Analytics 公司.Cortellis 数据库[EB/OL].(2022 — 08-31)[2025-08-30].https://www.cortellis.com/intelli-gence.
[7] 张勇慧.微生物天然药物化学研究[M].武汉:华中科技大学出版社,2019.
[8] FDA.GILENYA (fingolimod) capsules[EB/OL].(2010-09-21)[2025-08-25].https://www.accessdata.fda.gov/drugsat-fda_docs/label/2010/022527s000lbl.pdf.
[9] FDA.GILENYA (fingolimod) capsules,for oral use[EB/OL].(2024-06-25)[2025-08-25].https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022527s042lbl.pdf.
[10] FDA.TASCENSO ODT (fingolimod) orally disintegrating tablets[EB/OL].(2025-01-29)[2025-08-29].https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214962s003lbl.pdf.
[11] 林淘曦,余娜,黄璐.美国首仿药制度及专利挑战策略研究[J].中国新药杂志,2016,25 (19):2168-2173.
[12] 张晋瑜,刘玲,王勃,等.一株低温环境真菌的活性次级代谢产物研究[C].上海:中国菌物学会2015年学术年会论文摘要集,2015.
[13] FDA.MAYZENT^® (siponimod) tablets,for oral use[EB/OL].(2024-06-30)[2025-08-29].https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214962s003lbl.pdf.
[14] LAMB YN.Ozanimod:first approval[J].Drugs,2020, 80 (8):841-848.
[15] SANDBORN WJ,FEAGAN BG,HAENS G,et al.Ozanimod as induction and maintenance therapy for ulcerative colitis[J].N Engl J Med,2021,385 (14):1280-1291.
[16] FDA.PONVORY^® (ponesimod) tablets,for oral use[EB/OL].(2024-06-06)[2025-08-29].https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213498s005s006lbl.pdf.
[17] 黄璐,古双喜,洪怡.选择性转染重排酪氨酸激酶抑制剂概述及其专利研究[J].中国医药工业杂志,2021,52 (10): 1291-1296.
[18] 黄璐,钱丽娜,张晓瑜,等.医药领域的专利保护与专利布局策略[J].中国新药杂志,2017,26 (2):139-144.